Tectonic Therapeutic, Inc.

AVRO

US8789721086

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 18:59:28 16/07/2024 BST			5-day change	1st Jan Change
17.34 ^USD	+4.11%		+8.41%	+2.02%

07-01	Tectonic Therapeutic, Inc.(NasdaqGM:TECX) added to Russell 3000E Index	CI
07-01	Tectonic Therapeutic, Inc.(NasdaqGM:TECX) added to Russell Microcap Index	CI

Tectonic Therapeutic, Inc.(NasdaqGM:TECX) added to Russell 3000E Value Index

July 30, 2024

Latest news about Tectonic Therapeutic, Inc.

Tectonic Therapeutic, Inc.(NasdaqGM:TECX) added to Russell 3000E Index	06-30	CI
Tectonic Therapeutic, Inc.(NasdaqGM:TECX) added to Russell Microcap Index	06-30	CI
Tectonic Therapeutic, Inc.(NasdaqGM:TECX) added to Russell Microcap Value Index	06-30	CI
Tectonic Therapeutic, Inc.(NasdaqGM:TECX) added to Russell 3000E Value Index	06-30	CI
Avrobio Closes Merger With Tectonic Therapeutic	06-20	MT
Tectonic Therapeutic, Inc. announced that it has received $96.599856 million in funding from Tas Partners, LLC	06-19	CI
AVROBIO, Inc.(NasdaqGS:AVRO) dropped from NASDAQ Composite Index	06-19	CI
Tectonic Therapeutic, Inc. completed the acquisition of AVROBIO, Inc. from a group of shareholders in a reverse merger transaction.	06-19	CI
Avrobio Insider Bought Shares Worth $971,493, According to a Recent SEC Filing	05-15	MT
AVROBIO, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
North American Morning Briefing : Investors -2-	03-21	DJ
AVROBIO, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-14	CI
Transcript : AVROBIO, Inc., Tectonic Therapeutic, Inc. - M&A Call	01-30
Tectonic Therapeutic, Inc. announced that it expects to receive $96.599856 million in funding from Tas Partners, LLC	01-29	CI
AVROBIO, Inc. entered into an agreement to acquire Tectonic Therapeutic, Inc.	01-29	CI
North American Morning Briefing : S&P 500 Eyes -2-	12-19	DJ
Mizuho Securities Cuts Avrobio Price Target to $2 From $5, Buy Rating Kept	12-18	MT
North American Morning Briefing : Caution Dominates Ahead of CPI Print	11-14	DJ
AVROBIO, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
North American Morning Briefing : China Angst -2-	15/08/23	DJ
AVROBIO, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/08/23	CI
Wells Fargo Adjusts Price Target on AVROBIO to $2 From $2.50, Maintains Overweight Rating	13/07/23	MT
North American Morning Briefing : Optimism Set to -2-	13/07/23	DJ
Sector Update: Health Care Stocks Slipping Late Wednesday	12/07/23	MT
Sector Update: Health Care Stocks Softer in Afternoon Trading	12/07/23	MT

Chart Tectonic Therapeutic, Inc.

Duration

Period

More charts

AVROBIO, Inc. is a gene therapy company. The Company is focused on developing potentially curative hematopoietic stem cells (HSC) gene therapies to treat patients with rare diseases following a single dose treatment regimen. The gene therapies that the Company is engaged in developing employ HSCs that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The Company's development focus has been on a group of rare genetic diseases referred to as lysosomal disorders, primarily managed with enzyme replacement therapies (ERTs). Its pipeline is comprised of three HSC gene therapy programs, which include AVR-RD-02 for the treatment of Gaucher disease type 1 and type 3; AVR-RD-03 for the treatment of Pompe disease, and AVR-RD-01 for the treatment of Fabry disease.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

16.65 USD

Average target price

76 USD

Spread / Average Target

+356.46%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
TECTONIC THERAPEUTIC, INC.	+2.02%	245M
VERTEX PHARMACEUTICALS INCORPORATED	+20.13%	127B
REGENERON PHARMACEUTICALS, INC.	+24.29%	117B
ARGENX SE	+25.44%	27.67B
BIONTECH SE	-18.14%	20.33B
GENMAB A/S	-15.17%	16.79B
BEIGENE, LTD.	-15.57%	15.63B
NEUROCRINE BIOSCIENCES, INC.	+12.86%	14.84B
WUXI APPTEC CO., LTD.	-47.10%	14.65B
SAREPTA THERAPEUTICS, INC.	+56.04%	14.43B

Bio Therapeutic Drugs